Chlamydia trachomatis, the causative agent of Chlamydia, is a Gram negative bacteria. Transmission of the bacteria occurs via contact with infected bodily fluids which then infect mucosal membranes. It can be transmitted from mother to child during pregnancy and infect the eyes causing conjunctivitis. The genital infection causes urethritis, epididymitis and prostatitis in males and Pelvic Inflammatory Disease (PID) in females with an increased risk of contracting HIV. The infection can be treated with a course of antibiotics. Sexually transmitted infections in females are most often asymptomatic, but can be noticeable in chronic pain of the pelvic region, vaginal bleeding and painful urination. Infection of the ovaries, fallopian tubes or uterus causes Pelvic Inflammatory Disease (PID) which can lead to difficulties in conceiving, increased risk of ectopic pregnancy or infertility. Infections in males are more likely to be symptomatic, causing painful urination, discharge from the penis and swollen testicles and may eventually cause infertility if left untreated.
Chlamydia TaqMan PCR Kit, 100 reactions
Ready to use format, including Master Mix for the target and PCR control to monitor for PCR inhibition and validate the quality
Specific Primer and Probe mix for the pathogen/virus/viroid of interest
Primer and Probe mix
Positive and negative control to confirm the integrity of the kit reagents
Chlamydia TaqMan PCR Probe/Primer Set and Controls, 100 reactions
Specific Primer/Probe mix and Positive Control for the pathogen/virus/viroid of interest
Nuclease-free water
Can be used together with Norgen’s PCR Master Mix (#28007) or customer supplied master mix
For research use only and NOT intended for in vitro diagnostics.
Storage Conditions and Product Stability All kit components can be stored for 2 years after the date of production without showing any reduction in performance.
All kit components should be stored at -20°C upon arrival.
resDNASEQ E.coli Residual DNA Quantitation kit (Without DNA Control)
Product Info
Document
Product Info
Description
Features of the sDNASEQ E.coli Residual DNA
Quantitation kit include:
Simpler and Rapid
Only three steps will be need for Sample Preparation and All components of the Sample Preparation Kit can be stored at room temperature.
Only one Reagent for qPCR;
Only 1.5 hours will be needed for the whole test.
Accurate
Perfect amplification curve, good amplification efficiency and good precision.
Highly sensitive quantitation using proven TaqMan™ real-time qPCR technology.
Limit of Detection (LOD): 1 pg/mL; Limit of Quantification (LOQ): 5 pg/mL
The recovery rate of different concentration samples in the linear range is between 70% and 130%
Kit Performance
Fig 1. Only three steps will be need for Sample Preparation and only 20 minitutes will be taken for Sample Preparation.
Fig 2. Seven concentration samples of 5fg/μL, 10fg/μL, 20fg/μL, 30fg/μL, 300fg/μL, 3pg/μL, 30pg/μL, 300pg/μL were detected. CV of each concentration was < 30%, Regression coefficient associated with standard solutions was 0.99975, and amplification efficiency was 100.068%.
Fig 3. Four concentration samples of 5fg/μL, 10fg/μL, 20fg/μL, and 30fg/μL were detected, and 10 multiple holes were detected for each concentration. The detection values of 5fg/μL and above were CV <30%.
Fig 4. DNA recovery can be determined by including samples spiked with known DNA amounts which are prepared from the corresponding DNA standards. Typically, the range for this value varies from 70% to 130%.
Fig 5. Only one Reagent for qPCR MIX.
Document
Note: Price not include shipment & duty, contact us to get full quote.
The resDNASEQ E.coli Residual DNA Quantitation kit is designed for the quantification of residual DNA from E. coli, in cell lines which are used for production of biopharmaceutical products. The resDNASEQ E.coli Residual DNA Quantitation kit use TaqManTM quantitative PCR to perform rapid, specifc quantitation of femtogram levels of residual host-cell or plasmid DNA. The kit was developed to meet the sensitivity requirements defined by WHO (10 ng E. coli DNA per therapeutic dose).